Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Psoriasis drug tildrakizumab tested in everyday practice

NCT ID NCT04203693

Disease control Sponsor: Almirall, S.A. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This observational study followed 331 adults with moderate-to-severe plaque psoriasis who were treated with tildrakizumab (Ilumetri) as part of their routine care. Researchers tracked how much the skin cleared and how quality of life improved over up to two years. The goal was to see if the drug works as well in real life as it did in earlier clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tildrakizumab (Ilumetri)
What this could lead to
If successful, this study could confirm that tildrakizumab works well and is safe for long-term use in everyday medical practice for people with moderate-to-severe plaque psoriasis.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by factors like patient selection. It cannot prove cause and effect, and long-term safety data are still limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

331 people

The number who actually took part.

Started

Oct 2019

Finished

May 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult male and female patients with moderate-to-severe chronic plaque psoriasis.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Written informed consent form. * Age \>= 18years. * Moderate to severe chronic plaque psoriasis diagnosis. * Participants who have participated in Tildrakizumab (Ilumetri®) clinical trials (Cohort 1) OR participants who, according to the physician's therapeutic decision, should start the treatment with Tildrakizumab (Ilumetri®) (Cohort 2). Exclusion Criteria: * Unable to comply with the requirements of the study or who in the opinion of the study physician should not participate in the study. * Participants meeting any of the exclusion criteria specified in the summary of product characteristics (SmPC) of Ilumetri®.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Plaque psoriasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Plaque psoriasis

Contacts and locations

Locations

  • Investigational Site 1

    Nice, France

  • Investigational Site 1

    Augsburg, Germany

  • Investigational Site 1

    Arezzo, Italy

  • Investigational Site 10

    Cologne, Germany

  • Investigational Site 10

    Roma, Italy

  • Investigational Site 11

    Lübeck, Germany

  • Investigational Site 11

    Roma, Italy

  • Investigational Site 12

    München, Germany

  • Investigational Site 12

    Rozzano, Italy

  • Investigational Site 13

    Merzig, Germany

  • Investigational Site 14

    Oberursel, Germany

  • Investigational Site 15

    Quedlinburg, Germany

  • Investigational Site 2

    Berlin, Germany

  • Investigational Site 2

    Brescia, Italy

  • Investigational Site 3

    Bochum, Germany

  • Investigational Site 3

    Catania, Italy

  • Investigational Site 4

    Erlangen, Germany

  • Investigational Site 4

    Florence, Italy

  • Investigational Site 5

    Greifswald, Germany

  • Investigational Site 5

    Genova, Italy

  • Investigational Site 6

    Hamburg, Germany

  • Investigational Site 6

    Lecce, Italy

  • Investigational Site 7

    Halle, Germany

  • Investigational Site 7

    Modena, Italy

  • Investigational Site 8

    Kiel, Germany

  • Investigational Site 8

    Roma, Italy

  • Investigational Site 9

    Kiel, Germany

  • Investigational Site 9

    Roma, Italy

  • Investigational site 1

    Breda, Netherlands

  • Investigator Site 1

    Baden, Austria

  • Investigator Site 1

    Brussels, Belgium

  • Investigator Site 2

    Vienna, Austria

  • Investigator Site 2

    Charleroi, Belgium

  • Investigator Site 2

    Poitiers, France

  • Investigator Site 3

    Genk, Belgium

  • Investigator Site 4

    Ghent, Belgium

  • Investigator Site 5

    Herstal, Belgium

  • Investigator Site 6

    Jette, Belgium

  • Investigator Site 7

    Lede, Belgium

  • Investigator Site 8

    Leuven, Belgium

  • Investigator Site 9

    Mons, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.